HLX 70
Alternative Names: HLX-70Latest Information Update: 28 Jun 2022
At a glance
- Originator Shanghai Henlius Biotech
- Class Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 23 Jun 2022 Shanghai Henlius Biotech withdraws a phase I pharmacokinetic trial for COVID-2019 infections (In volunteers, In adults), prior to enrolment, due to the sponsor's strategy (IV, Infusion) (NCT05429385)
- 15 Apr 2022 Hengenix Biotech withdraws a phase I pharmacokinetic trial for COVID-2019 infections in healthy volunteers (NCT04561076)
- 15 Dec 2021 Discontinued - Preclinical for COVID-2019 infections in China (IV) (Shanghai Henlius Biotech pipeline; December 2021)